Dopamine agonists and weight changes in prolactinoma patients
Authors' conclusion
The use of dopamine agonists for a duration of about 12 months did not result in statistically significant weight loss among patients with prolactinoma.
Study context
- Population
- Prolactinoma patients treated with dopamine agonists, referred to one pituitary clinic 2010–2020
- Participants
- 91 patients
- Exposure
- Females vs Males
- Femalesn = 47
- Malesn = 44
- Outcome
- Weight change during dopamine agonist treatment
- Follow-up
- 12 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Weight change · over the treatment period (12 months)
Men: mean weight loss
7.8 pounds
Women: mean weight loss
1.1 pound
Observational data: associations, not effects.
Further findings
Baseline prolactin
Ng/ml
- Men: mean prolactin (higher)
- 779.95
- Females: initial prolactin
- 433
Prolactin drop · 0–3 months
ng/mL
- Men: mean prolactin drop
- 644
- Women: mean prolactin drop
- 257
Prolactin over 1 year · 12 months
- Prolactin decreased to normal levels over one year, steepest drop between 0 and 3 months
Original publication
Dopamine agonists and weight changes in prolactinoma patients. Pituitary. Published 5 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →